Scarica l'app Stockscreener
50.80
1.95%
-0.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$51.78
Aprire:
$50.69
Volume 24 ore:
1.34M
Relative Volume:
0.45
Capitalizzazione di mercato:
$125.77B
Reddito:
$43.23B
Utile/perdita netta:
$6.79B
Rapporto P/E:
12.68
EPS:
4.0051
Flusso di cassa netto:
$9.17B
1 W Prestazione:
-1.78%
1M Prestazione:
+0.30%
6M Prestazione:
-1.76%
1 anno Prestazione:
+4.66%
Intervallo 1D:
$50.48
$50.94
Intervallo di 1 settimana:
$50.48
$52.68
Portata 52W:
$44.62
$60.12
Sanofi Adr Stock (SNY) Company Profile
Nome
Sanofi Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta SNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
50.80 | 125.77B | 43.23B | 6.79B | 9.17B | 4.0051 |
|
LLY
Lilly Eli Co
|
1,035.38 | 914.44B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
199.59 | 480.85B | 92.15B | 25.12B | 20.46B | 10.36 |
|
AMGN
Amgen Inc
|
344.45 | 184.00B | 35.89B | 7.01B | 11.54B | 12.94 |
|
ABBV
Abbvie Inc
|
234.67 | 413.57B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
96.71 | 230.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-03-21 | Iniziato | Goldman | Neutral |
| 2025-01-30 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Reiterato | Argus | Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Downgrade | Stifel | Buy → Hold |
| 2023-09-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-28 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Ripresa | Morgan Stanley | Overweight |
| 2022-08-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Downgrade | UBS | Buy → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-09-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Sell |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-03-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-02-11 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-01-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-09-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Iniziato | Bernstein | Outperform |
| 2019-08-14 | Aggiornamento | UBS | Neutral → Buy |
| 2018-12-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-11-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-03-23 | Aggiornamento | Liberum | Hold → Buy |
| 2018-01-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Aggiornamento | HSBC Securities | Reduce → Hold |
Mostra tutto
Sanofi Adr Borsa (SNY) Ultime notizie
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION - GlobeNewswire Inc.
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm
UPDATE - GlobeNewswire Inc.
Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study - The Globe and Mail
Sanofi (SNYNF) Gets a Buy from J.P. Morgan - The Globe and Mail
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm
SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent
UBS Reaffirms Their Buy Rating on Sanofi (SNYNF) - The Globe and Mail
Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail
BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals
Sanofi Expands Insulin Savings Program To Cover All US Patients - Sahm
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability - Sahm
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Sahm
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS® - Ariva
Leerink Partners Sticks to Their Buy Rating for Sanofi (SNY) - The Globe and Mail
What's Going On With Nektar Therapeutics Stock On Thursday? - Sahm
Why Is Sanofi Stock Falling Thursday? - Sahm
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Sahm
Sanofi Adr Azioni (SNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.03%
0.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):